-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Downgrades KalVista Pharmaceuticals to Neutral, Lowers Price Target to $27

Benzinga·05/01/2026 10:42:03
Listen to the news
HC Wainwright & Co. analyst Andrew S. Fein downgrades KalVista Pharmaceuticals (NASDAQ:KALV) from Buy to Neutral and lowers the price target from $37 to $27.